SciSparc Ltd. announced that it has successfully completed the manufacturing of and delivered its innovative SCI- 210 treatment, in accordance with its initiation of enrollment for the clinical trial at the Soroka Medical Center of pediatric patients who have Autism Spectrum Disorder. The Company?s proprietary SCI- 210 treatment combines cannabidiol-rich oil (?CBD?) and CannAmide?, SciSparc?s proprietary palmitoylethanolamide-based tablets. The clinical trial will rigorously examine the safety, tolerability, and efficacy of SCI- 210, in comparison to CBD monotherapy, for the treatment of ASD.

Designed as a randomized, double-blind, placebo-controlled clinical trial with cross-over, the clinical trial will span 20 weeks and enroll 60 children. The clinical trial?s primary efficacy endpoints include three rigorous assessments: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) scale, administered by healthcare professionals; and the determination of the effective therapeutic dosage.